SER150 vs Placebo in Diabetic Kidney Disease

Inclusion Criteria: * Participant has had stable T2D for 3 months prior to screening * Participant has albuminuria defined by urine UACR ≥ 200 mg/g creatinine as a mean of three independent samples of first urine void of the day * Participant is receiving stable antidiabetic treatment. Antidiabetic treatment includes all drugs given for the treatment of T2D * Participant is in treatment with ACEi or ARB, with eGFRcrea lower than 75 mL/minute /1.73 m\^2 and above 15 mL/minute/1.73 m\^2 (CKD-EPI formula) and will not, in the opinion of the investigator, become a candidate for renal dialysis whilst on the study * Participant is determined to be overtly healthy as determined by Investigator review of their medical history, physical examination, laboratory tests, and cardiac monitoring. It is anticipated that, whilst some of the participant's results may be different to that of a completely healthy individual, the Investigator will review the participant's individual results to ensure they are as healthy as can be expected give the participant's current health status * Participant has ASA physical status, health class 2, 3 or 4 * Participant has blood pressure ≤ 160 mmHg systolic, and ≤ 100 mmHg diastolic * Participant has normal electrocardiogram * Participant has glycosylated hemoglobin (HbA1c) ≤ 10% * Participant has prothrombin within normal values * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those …